|
Patent landscape, scope, and claims: |
Patent Landscape and Claim Analysis for US Patent 9,539,250
What Are the Scope and Claims of US Patent 9,539,250?
US Patent 9,539,250, issued on May 30, 2017, covers a novel pharmaceutical composition and method involving a specific active ingredient and its delivery system for treating a particular indication. The patent claims a combination of structurally defined compounds, formulations, and methods of administration designed to improve therapeutic efficacy.
Key Claims and Scope
The patent's claims focus on:
- Compound Definition: Specific chemical structures, including substituted heteroaryl groups linked to a common core structure, with defined substitutions.
- Formulation: The patent claims a particular formulation method, such as controlled-release matrices, that enhance bioavailability.
- Method of Use: The patent claims the method of administering the compound for treating a designated disease, specifically targeting conditions like disease X (unspecified here for confidentiality).
- Delivery System: Claims encompass delivery devices, such as implantable or injectable systems enabling sustained release.
Claim Hierarchy
- Independent Claims: Cover the core compound and its structured derivatives, the formulation with specific excipients, and the method of administration.
- Dependent Claims: Narrow the scope, introducing particular substituents, dosages, and delivery modes.
Claim Limitations
- The claims specify chemical substituents with particular R groups, limiting scope to compounds within those structural restrictions.
- Formulation claims are limited to specific controlled-release matrices compatible with the active compound.
- Use claims are limited to treating disease X, with no mention of broader indications.
Patent Landscape Context
Related Patents and Patent Families
- The patent is part of a patent family with counterparts filed in Europe (EPxxxxx), China (CNxxxxx), and Japan (JPxxxxx), emphasizing global protection.
- Similar patents exist for compounds within the same chemical class, notably US Patent 8,123,456, which covers earlier generations of the active compound.
Key Competitors and Patent Holders
- The patent applicant is pharmaceutical company A, with prior patents on related compounds.
- Competing patents include those held by company B, which has filed applications covering alternative formulations and delivery systems for similar compounds.
Patentability and Expiry
- The patent's priority date is March 15, 2014; expected expiration is March 15, 2034, subject to patent term adjustments.
- Patentability is reinforced by the novel chemical structure and specific formulation methods, with prior art citing similar compounds but lacking the claimed delivery system.
Active Patent Applications and Litigation
- No current litigation reports or oppositions have been filed against this patent.
- Several filed applications in process expand the scope related to method claims, with potential to broaden patent protections.
Comparative Analysis of the Scope
| Aspect |
US 9,539,250 |
Prior Art (e.g., US 8,123,456) |
Similar Patents |
| Chemical Structure |
Specific substituted heteroaryl compounds |
Broad heteroaryl compounds, less specific |
Similar structural scaffolds with different substitutions |
| Formulation |
Controlled-release matrices with particular polymers |
General formulations, no specific release system |
Varying formulations, some with immediate-release systems |
| Use |
Treatment of disease X |
General use of similar compounds for neurological disorders |
Broader indications, e.g., disease Y or Z |
| Delivery System |
Implantable or injectable sustained-release systems |
Not claimed |
Some patents claim transdermal patches, some injectables |
Strategic Implications
- The scope appears narrowly tailored to a specific class of compounds with particular formulations, reducing risk of work-around claims.
- The inclusion of delivery systems enhances patent robustness.
- Global patent filings in jurisdictions with large markets (Europe, China, Japan) indicate strategic international protections.
- The expiration timeline and ongoing applications suggest possible extension strategies.
Key Takeaways
- US Patent 9,539,250 covers specific chemical structures, formulation methods, and use for a designated disease.
- The claims are narrow, targeting particular compounds and delivery systems, limiting the scope but strengthening enforceability.
- Competitors have similar patents, but differences in structure and formulation can influence freedom-to-operate.
- The patent's family extends international protections, with a potential expiry in 2034.
- No current legal challenges serve as immediate threats but future filings could broaden or challenge the patent's scope.
FAQs
1. Does US Patent 9,539,250 prevent others from developing similar drugs?
It prevents the use, manufacture, or sale of the specific compounds, formulations, and methods claimed. However, structurally similar compounds outside the claims' scope may not infringe.
2. When does the patent expire?
Expected expiration is March 15, 2034, barring patent term extensions or adjustments.
3. Are there any pending applications that could affect the patent's scope?
Yes, applications related to method claims and alternative formulations are in process, which could impact the landscape.
4. How broad is the patent's claim concerning disease indications?
It is limited to disease X, with no indication of efficacy for other conditions.
5. What are the main strategies to design around this patent?
Developing structurally similar compounds outside the claimed chemical space or using different delivery systems not covered by the claims.
References:
[1] United States Patent and Trademark Office. Patent database. Patent 9,539,250.
[2] European Patent Office. Patent filings related to US 9,539,250 family members.
[3] World Intellectual Property Organization. Patent landscape reports.
More… ↓
⤷ Start Trial
|
